People: Transition Therapeutics Inc (TTHI.W)


TTHI.W on CBOE When Trading NASDAQ Global Select Market

3.51USD
18 Jun 2013
Price Change (% chg)

$-0.03 (-0.85%)
Prev Close
$3.54
Open
$3.47
Day's High
$3.57
Day's Low
$3.46
Volume
405
Avg. Vol
51
52-wk High
$3.70
52-wk Low
$1.90

Search Stocks

Summary

Name Age Since Current Position

Tony Cruz

 59 1999 Chairman of the Board, Chief Executive Officer

Nicole Rusaw-George

 39 2012 Chief Financial Officer

Bruce Connop

 43 2012 Vice President - Non-Clinical & Pharmaceutical Development

Aleksandra Pastrak

 46 2011 Vice President - Clinical Development and Medical Officer

Carl Damiani

 39 2007 Vice President - Business Development

Louis Alexopoulos

 1998 Secretary

Michael Ashton

 67 2012 Lead Independent Director

Paul Baehr

 69 2002 Independent Director

Christopher Henley

 52 2000 Independent Director

Gary Pace

 65 2012 Independent Director
» Insider Trading

Biographies

Name Description

Tony Cruz

Nicole Rusaw-George

 Ms. Nicole Rusaw-George, C.A., is Chief Financial Officer of Transition Therapeutics Inc. Prior thereto, VP, Finance of the Corporation since July 2008, prior thereto, Director of Finance of the Corporation since June 2005.

Bruce Connop

 Dr. Bruce Connop is Vice President - Non-Clinical & Pharmaceutical Development of Transition Therapeutics Inc. He has been with Transition since 2006 and served as Sr. Director, Nonclinical Drug Development until he was appointed VP, Non-Clinical & Pharmaceutical Development in 2012. With his experience in pharmacology, toxicology and manufacturing he is responsible for a broad range of activities and has made contributions to the advancement of pipeline products. Dr. Connop holds a Ph.D. from Queen’s University and has had experience at other biotech and pharmaceutical companies.

Aleksandra Pastrak

 Dr. Aleksandra Pastrak is Vice President - Clinical Development and Medical Officer of Transition Therapeutics Inc. Prior thereto, VP Research and Medical Officer of the Corporation since July 2007, prior thereto, VP, Research of the Corporation since May 2005.

Carl Damiani

 Mr. Carl Damiani is Vice President - Business Development of Transition Therapeutics Inc. Prior thereto, Director of Business Development of the Corporation since October 2003.

Louis Alexopoulos

 Mr. Louis Alexopoulos is Secretary of Transition Therapeutics Inc. Mr. Alexopoulos is a Barrister and Solicitor at Sotos Associates LLP, law firm.

Michael Ashton

 Mr. Michael Richard Dwyer Ashton is Lead Independent Director of Transition Therapeutics Inc. Mr. Ashton has been an independent consultant to the pharmaceutical industry since March 2006. Prior thereto, he was the Chief Executive Officer of SkyePharma PLC. He has 30 years of experience in the Pharmaceutical industry having worked for Merck, Pfizer, Purepac and Faulding, where Mr. Ashton was Chairman, President and CEO. Mr. Ashton currently sits on boards of directors of the following public companies; Hikma Pharmaceuticals PLC, and Proximagen Neuroscience PLC.

Paul Baehr

 Mr. Paul Baehr is Independent Director of Transition Therapeutics Inc. Mr. Baehr has a B.A. from the University of British Columbia. He is currently President, Chief Executive Officer and Chairman of IBEX Technologies Inc., a biotechnology company listed on the TSX under the symbol “IBT”. Previously, Mr. Baehr was an Executive Vice President at Sterling Winthrop and prior thereto a Senior Vice President at CIBA-GEIGY Pharmaceuticals, both of which are pharmaceutical companies. In addition, Mr. Baehr currently sits on the board of directors of IBEX Technologies Inc., a public company.

Christopher Henley

 Mr. Christopher M. Henley is Independent Director of Transition Therapeutics Inc. Mr. Henley has a B.A. from Memorial University and an MBA from Dalhousie University. He has completed the Institute of Corporate Directors Education Program at the Rotman School of Management, University of Toronto and holds the professional designation ICD.D. He is currently founder and President of Henley Capital Corporation, an exempt market dealer specializing in mergers and acquisitions, financing and advisory services to companies covering the full spectrum of high technology and emerging companies. Previously, Mr. Henley was the head of investment banking in Toronto at what was then Canada’s independent employee-owned investment dealer and ran the High Technology and Communications practice. Mr. Henley is a former Chair of the Toronto Port Authority where he also chaired the Corporate Governance, Nominating and Human Resources Committee and was a member of the Audit Committee and a former member of the board and audit committee of Ontario Transportation Capital Corporation, a Government of Ontario Crown Corporation that, through a public partnership, developed Highway 407 in Toronto, Ontario, the first all-electronic toll highway in the world. Mr. Henley is also a founding member of the National Angel Organization in Canada and the Ministers’ Technology Advisory Group (“MTAG”) for the Province of Ontario. He is also a former Chair of the MTAG Task Force on Access to Capital, a former member of the Advisory Board, Faculty of Business Administration, Memorial University of Newfoundland and an active member of the Institute of Corporate Directors. Mr. Henley currently sits on a number of boards of directors including West Park Healthcare Centre and the McMichael Canadian Art Foundation.

Gary Pace

 Dr. Gary W. Pace, Ph.D., is Independent Director of Transition Therapeutics Inc. Dr. Pace is Chairman and founder of Sova Pharmaceuticals Inc. since May, 2010, Director and consultant of QRxPharma, a biotechnology company, since April 13, 2007; prior thereto, Co-founder, Chairman and Chief Executive Officer of QRxPharma since November 2002.

Basic Compensation

Name Fiscal Year Total

Tony Cruz

 746,279

Nicole Rusaw-George

 298,627

Bruce Connop

 238,384

Aleksandra Pastrak

 391,325

Carl Damiani

 308,451

Louis Alexopoulos

 --

Michael Ashton

 --

Paul Baehr

 --

Christopher Henley

 --

Gary Pace

 --
As Of 29 Jun 2012

Options Compensation

Name Options Value

Tony Cruz

 466,667 941,333

Nicole Rusaw-George

 0 0

Bruce Connop

 0 0

Aleksandra Pastrak

 237,408 459,566

Carl Damiani

 192,777 458,363

Louis Alexopoulos

 0 0

Michael Ashton

 0 0

Paul Baehr

 0 0

Christopher Henley

 0 0

Gary Pace

 0 0

Insider Trading

Name Shares Traded Price

SCHULER JACK W

 1,925,926 $1.35
» Full list on Insider Trading
Search Stocks